Study Summary
T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.
Want to learn more about this trial?
Request More InfoInterventions
CD7 CAR-T cellsBIOLOGICAL
patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Li Yu | Shenzhen | Guangdong | China |